Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2022 Results Conference Call May 9, 2022 4:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - Chairman and CEO John Poyhonen - President and Chief Commercial Officer Kimberly Manhard - EVP, Drug Development and Board Director Conference Call Participants Brandon Folkes - Cantor Fitzgerald Josh Schimmer - Evercore ISI Serge Belanger - Needham and Company Boris Peaker - Cowen Kelly Shi - Jefferies Operator Good day, ladies and gentlemen, and than ...

Heron Update April 11, 2022 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation, and involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed ...

| --- | --- | --- | |-----------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Heron Update | | | | | | | | Q4 2021 Earnings Call | | | | | | | | | | | Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation, and involve substantial risks and uncer ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2021 Results Conference Call February 28, 2022 4:30 PM ET Â Company Participants David Szekeres - EVP and COO Barry Quart - Chairman and CEO John Poyhonen - President and Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Josh Schimmer - Evercore Serge Belanger - Needham Kelly Shi - Jefferies Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q4 2021 Earnings Conference. As ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2021 Results Earnings Conference Call November 3, 2021 4:15 PM ET Company Participants David Szekeres - Executive Vice President, Chief Operating Officer Barry Quart - Chief Executive Officer and Chairman of the Board John Poyhonen - President and Chief Commercial Officer; Kimberly Manhard - Executive Vice President, Drug Development and Director Conference Call Participants Joshua Schimmer - Evercore ISI Brandon Folkes - Cantor Fitzgerald Boris Peaker - Cowen Serge ...

| --- | --- | --- | |-------------------------------------------|-------|-------| | | | | | | | | | Heron Therapeutics Update September 2020 | | | | | | | | | | | Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation, and involve substantial risks and uncertainties that ...

| --- | --- | --- | |----------------------------------|-------|-------| | | | | | | | | | | | | | | | | | Heron Therapeutics | | | | Leerink Update February 24, 2020 | | | | | | | | | | | Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation, and involve substantial ris ...

| --- | --- | --- | |--------------------|-------|-------| | | | | | | | | | | | | | Heron Therapeutics | | | | Update | | | | | | | | | | | | DEC 3, 2019 | | | | | | | | | | | Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation, and involve substantial risks and uncer ...

| --- | --- | --- | --- | |--------------------------------------------------|-------|-------|-------| | | | | | | Heron Therapeutics Corporate Update OCT 2, 2019 | | | | | | | | | Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation, and involve substantial risks and u ...

Corporate Update June 5, 2019 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation, and involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those express ...